Structure-Based Networks for Drug Validation
Classifying chemicals according to putative modes of action (MOAs) is of paramount importance in the context of risk assessment. However, current methods are only able to handle a very small proportion of the existing chemicals. We address this issue by proposing an integrative deep learning architecture that learns a joint representation from molecular structures of drugs and their effects on human cells. Our choice of architecture is motivated by the significant influence of a drug's chemical structure on its MOA. We improve on the strong ability of a unimodal architecture (F1 score of 0.803) to classify drugs by their toxic MOAs (Verhaar scheme) through adding another learning stream that processes transcriptional responses of human cells affected by drugs. Our integrative model achieves an even higher classification performance on the LINCS L1000 dataset - the error is reduced by 4.6%. We believe that our method can be used to extend the current Verhaar scheme and constitute a basis for fast drug validation and risk assessment.
Code (0)
등록된 구현이 없습니다.
Similar Papers 제목 키워드 기반
Pharmacology Knowledge Graphs: Do We Need Chemical Structure for Drug Repurposing?
The contributions of model complexity, data volume, and feature modalities to knowledge graph-based drug repurposing remain poorly quantified under rigorous temporal validation. We constructed a pharmacology knowledge gr…
Knowledge Graph EmbeddingGraph Neural NetworkKnowledge GraphsDiSPA: Differential Substructure-Pathway Attention for Drug Response Prediction
Accurate prediction of drug response in precision medicine requires models that capture how specific chemical substructures interact with cellular pathway states. However, most existing deep learning approaches treat che…
Drug Response PredictionSynthesis-driven design of 3D molecules for structure-based drug discovery using geometric transformers
Finding drug-like compounds with high bioactivity is essential for drug discovery, but the task is complicated by the high cost of chemical synthesis and validation. With their outstanding performance in de novo drug des…
Drug DesignDrug DiscoveryLeveraging Partial SMILES Validation Scheme for Enhanced Drug Design in Reinforcement Learning Frameworks
SMILES-based molecule generation has emerged as a powerful approach in drug discovery. Deep reinforcement learning (RL) using large language model (LLM) has been incorporated into the molecule generation process to achie…
Deep Reinforcement LearningDrug DesignDrug DiscoveryLarge Language Model+1subCellSAM: Zero-Shot (Sub-)Cellular Segmentation for Hit Validation in Drug Discovery
High-throughput screening using automated microscopes is a key driver in biopharma drug discovery, enabling the parallel evaluation of thousands of drug candidates for diseases such as cancer. Traditional image analysis …
Cell SegmentationDrug Discovery